U.S. markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.10 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.89 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    -1.49 (-1.83%)
     
  • Gold

    1,668.30
    -0.30 (-0.02%)
     
  • Silver

    19.01
    +0.30 (+1.62%)
     
  • EUR/USD

    0.9801
    -0.0018 (-0.19%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • GBP/USD

    1.1166
    +0.0043 (+0.38%)
     
  • USD/JPY

    144.7200
    +0.2770 (+0.19%)
     
  • BTC-USD

    19,314.17
    -121.98 (-0.63%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Amyris, ImmunityBio Shares Trading Higher On COVID-19 Vaccine Joint Venture

·1 min read

Amyris Inc (NASDAQ: AMRS) and ImmunityBio (NASDAQ: IBRX) have completed their previously announced joint venture agreement to accelerate the commercialization of a next-generation COVID-19 vaccine.

  • Upon completion of human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as it is practically possible to deliver.

  • Related: Amyris, ImmunityBio Join Forces For Next-Gen COVID-19 RNA Vaccine.

  • The ability to 'mix and match' vaccine platforms through this new joint venture and ImmunityBio's multiple COVID vaccine platforms represents one of the most exciting approaches to ending COVID-19."

  • Further announcements will be made when the results of human trials are available.

  • Price Action: AMRS shares are up 10.80% at 6, and IBRX shares are up 17.30% at $7.30 during the market session on the last check Monday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.